LAG3 and neoplasm: Blockade of the FGL1/LAG-3 interaction by anti-FGL1 mAb or anti–LAG-3 mAb enhances antitumor immunity and shows therapeutic effects on an established mouse subcutaneous tumor model of the MC38 cell line (6).